Pleco Therapeutics

Leukaemia
#Acute Myeloid Leukaemia #FDA #Haematology #Oncology #Pleco Therapeutics

Positive FDA outcome for PTX-252 in acute myeloid leukaemia

Pleco Therapeutics, a clinical-stage biopharmaceutical company developing novel therapies for difficult-to-treat cancers, has announced a positive outcome from its Pre-Investigational New Drug (Pre-IND) meeting with the US Food and Drug Administration (FDA).   The meeting addressed the continued development of PTX-252, an intravenous (IV) formulation designed to treat… Read More

#News #Regulatory

Blood cancer
#Acute Myeloid Leukaemia #FDA #Oncology #Orphan drugs #Pleco Therapeutics #Rare disease

Novel leukaemia drug receives FDA Orphan Drug Designation

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Pleco Therapeutics’s lead compound PTX-252 for the treatment of acute myeloid leukaemia (AML). PTX-252 is a novel molecular entity developed to increase the sensitivity of cancer cells to chemotherapy. The FDA’s… Read More

#Cancer Research #News #Regulatory